Siltuximab is used in treatment of ?
**Core Concept**
Siltuximab is a monoclonal antibody that targets and binds to interleukin-6 (IL-6), a cytokine involved in the pathogenesis of various inflammatory and autoimmune disorders. By blocking IL-6 signaling, siltuximab aims to modulate the immune response and alleviate symptoms associated with these conditions.
**Why the Correct Answer is Right**
Siltuximab is primarily used in the treatment of multicentric Castleman's disease (MCD), a rare disorder characterized by excessive lymphoproliferation and cytokine production, including IL-6. By targeting IL-6, siltuximab reduces the cytokine's levels, leading to decreased inflammation and lymphoid hyperplasia. This mechanism of action is particularly effective in MCD patients who are resistant to conventional therapies.
**Why Each Wrong Option is Incorrect**
**Option A:** Siltuximab is not primarily used in the treatment of rheumatoid arthritis, although IL-6 has been implicated in the pathogenesis of this disease. Other treatments, such as tocilizumab, are more commonly used for this indication.
**Option B:** Siltuximab is not used in the treatment of multiple myeloma, a plasma cell malignancy. Other treatments, including proteasome inhibitors and immunomodulatory drugs, are more commonly used for this indication.
**Option C:** Siltuximab is not used in the treatment of psoriasis, a chronic inflammatory skin disease. Other treatments, including biologics targeting tumor necrosis factor-alpha (TNF-alpha) and other cytokines, are more commonly used for this indication.
**Clinical Pearl / High-Yield Fact**
When considering treatments for inflammatory and autoimmune disorders, it's essential to understand the specific cytokine pathways involved and the mechanisms of action of available therapies. Siltuximab's targeting of IL-6 highlights the importance of this cytokine in disease pathogenesis and the potential benefits of IL-6 inhibition in selected patient populations.
**Correct Answer: D. Multicentric Castleman's disease.**